Updated on 2025/04/19

写真a

 
-
 
Organization
Hospital Central Clinical Facilities Infection Control Department
External link

Education

  • Asahikawa Medical College   Faculty of Medicine

    - 2014.3

    　 More details

    Country： Japan

    researchmap

Research History

  • Asahikawa Medical College

    2016.4 - 2021.3

    　 More details

Professional Memberships

Papers

  • Real-World Treatment Outcomes in the First and Subsequent Coronavirus Disease 2019 (COVID-19) Hospital Clusters. International journal

    Yoshinobu Ohsaki, Takaaki Sasaki, Yasuhiro Umekage, Hiraku Yanada, Mariko Ishikawa, Ryohei Yoshida

    Cureus   17 ( 2 )   e78981   2025.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    OBJECTIVES: We experienced 10 coronavirus disease 2019 (COVID-19) hospital clusters between November 2020 and September 2023 and retrospectively examined whether the introduction of hospital cluster countermeasures improved patient prognosis. METHODS: We compared the first hospital cluster, in which infection prevention measures were insufficient, vaccines were not introduced, and antiviral drugs were not available (Phase 1), and the second or subsequent hospital clusters, when the abovementioned measures were improved (Phase 2). RESULTS: In Phase 2, the number of COVID-19 patient deaths within 30 days, infection rate in patients who shared a room with an infected patient, and infection rate among medical workers were reduced. Survival rates within 30 days did not differ significantly between Phases 1 and 2. In Phase 2, the survival rate was higher in females than in males and in groups treated with ensitrelvir and molnupiravir than in those treated with remdesivir. CONCLUSIONS: Countermeasures against hospital clusters require comprehensive measures, such as infection prevention, vaccination, rapid diagnosis, and antiviral drug administration. Antiviral drugs may shorten hospital clusters by rapidly suppressing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients.

    DOI： 10.7759/cureus.78981

    PubMed

    researchmap

  • Treatment of lung adenocarcinoma with chemotherapy helps mitigate chronic myeloid leukaemia progression: A case report. International journal

    Kazunori Nagasue, Ryotaro Kida, Ryota Shigaki, Kiichi Nitanai, Akari Yagita, Hiraku Yanada, Yasuhiro Umekage, Chie Mori, Yoshinori Minami, Takuya Funayama, Masayo Yamamoto, Mishie Tanino, Ryohei Yoshida, Takaaki Sasaki

    Oncology letters   29 ( 1 )   31 - 31   2025.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Treatment outcomes for inoperable advanced non-small cell lung cancer have improved in recent years. However, information on coexisting haematological tumours is lacking. The present patient was a 65-year-old woman with stage IVA lung adenocarcinoma. The patient was administered a combination of platinum therapy and immune checkpoint inhibitors. The patient was subsequently diagnosed with chronic myeloid leukaemia (CML) following leukocytosis. Carboplatin and pemetrexed combination therapy resulted in shrinkage of lung cancer. Improvements in peripheral blood leukocyte counts and bone marrow findings were observed. These results suggested that the treatment of lung cancer may control the course of CML.

    DOI： 10.3892/ol.2024.14777

    PubMed

    researchmap

  • Viability and diagnostic potential of tissues obtained through cryobiopsy. International journal

    Ryotaro Kida, Ryohei Yoshida, Kiichi Nitanai, Akari Yagita, Taeka Naraoka, Hiraku Yanada, Ryota Shigaki, Toshiyuki Tenma, Chie Mori, Yasuhiro Umekage, Mamiko Mitsumoto, Mishie Tanino, Yoshinori Minami, Takaaki Sasaki

    Respiratory investigation   62 ( 6 )   1220 - 1226   2024.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Transbronchial lung cryobiopsy is primarily used for diagnosing interstitial lung diseases and tumors, providing larger tissue samples with reduced tissue crushing than traditional biopsies. However, freezing during cryobiopsy may damage cells, potentially affecting diagnostic methods that require live cells, such as flow cytometry (FCM). We aimed to determine the extent of freezing-related cell damage in cryobiopsies using cells cultured in vitro. METHODS: To investigate the relationship between freezing duration and sample volume, Jurkat cells underwent freezing for durations ranging from 2 to 6 s, with 1-s intervals, using either 1-mm- or 1.7-mm cryoprobes. FCM was conducted to assess both cell viability (2, 4, and 6 s) and cell-surface molecule expression (3 and 6 s) over varying freezing times. Additionally, we describe a clinical case involving a 70-year-old man suspected of malignant lymphoma, in which tissue samples were obtained via both forceps biopsy and cryobiopsy methods to compare the pathological and cytological features between the methods. RESULTS: Harvested cell count increased with freezing duration, with a notable increase in viable cell percentage. Moreover, cells distant from the cryoprobe exhibited higher survival rates under milder freezing conditions. FCM revealed significantly higher marker expression levels in viable cryobiopsy samples than in non-viable samples. The clinical case demonstrated that cryobiopsy yields a significant proportion of live cells (>90%), with cytological findings consistent with those of non-frozen samples. CONCLUSIONS: Cryobiopsy may be beneficial for histopathological diagnosis, providing sufficient viable cells for FCM, and can be used for diagnosing malignant lymphomas and other pulmonary conditions.

    DOI： 10.1016/j.resinv.2024.10.011

    PubMed

    researchmap

  • 播種性BCG症に伴う血球貪食症候群の1例 Reviewed

    梅影泰寛, 八木田あかり, 梁田啓, 志垣涼太, 南幸範, 佐々木高明

    日本呼吸器学会誌   13 ( 2 )   83 - 87   2024.3

    　More details

    Authorship：Lead author,　Corresponding author   Language：Japanese   Publishing type：Research paper (scientific journal)  

    researchmap

  • Monitoring SARS-CoV-2 Viral Load and CD4+ T-cell Count After ART in a Patient Diagnosed With AIDS Following SARS-CoV-2 Infection: A Case Report. Reviewed International journal

    Yasuhiro Umekage, Mayumi Hatayama, Akari Yagita, Kiichi Nitanai, Hiraku Yanada, Ryota Shigaki, Yoshinori Minami, Takaaki Sasaki

    Cureus   15 ( 12 )   e51189   2023.12

    　More details

    Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    We describe the case of a 36-year-old man diagnosed with human immunodeficiency virus (HIV) following prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia. The patient had a complication of pneumocystis pneumonia. Upon initiating highly active antiretroviral therapy, we monitored HIV RNA levels, CD4+ T-cell count, SARS-CoV-2 viral load, and IgG antibodies against SARS-CoV-2. At 167 days post SARS-CoV-2 diagnosis, the patient's CD4+ T-cell count increased to 180 cells/μL. IgG antibodies against SARS-CoV-2 were undetectable despite a decreased SARS-CoV-2 viral load. HIV screening is necessary in cases of prolonged SARS-CoV-2 pneumonia or persistent SARS-CoV-2 shedding. When diagnosed with HIV infection, it is advisable to consider the possibility of pneumocystis pneumonia.

    DOI： 10.7759/cureus.51189

    PubMed

    researchmap

  • Detection of resistance mutations in patients with anaplastic lymphoma kinase-rearranged lung cancer through liquid biopsy. International journal

    Takaaki Sasaki, Ryohei Yoshida, Kiichi Nitanai, Takashi Watanabe, Toshiyuki Tenma, Ryotaro Kida, Chie Mori, Yasuhiro Umekage, Noriko Hirai, Yoshinori Minami, Shunsuke Okumura

    Translational lung cancer research   12 ( 7 )   1445 - 1453   2023.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Tyrosine kinase inhibitors (TKIs) significantly improve clinical outcomes in patients with non-small cell lung cancer due to anaplastic lymphoma kinase (ALK) gene rearrangement. However, the rate of relapse with TKIs is high owing to the development of resistance mutations during treatment. Repeated biopsies during disease progression are crucial for elucidating the molecular mechanisms underlying the development of resistance to ALK inhibitors. Analysis of cell-free DNA (cfDNA) obtained from plasma is a novel approach for tumor genotyping. METHODS: In this mixed prospective and retrospective observational cohort study, we investigated the clinical feasibility of continuous quantitative monitoring of ALK-acquired mutations in plasma obtained from patients with ALK+ non-small cell lung cancer by using a highly sensitive and specific droplet digital polymerase chain reaction (ddPCR) assay. We enrolled nine patients, including three treatment-naïve patients recently diagnosed with ALK+ non-small cell lung cancer via tissue biopsy and expected to receive ALK TKIs and six patients already receiving ALK TKIs. Plasma samples were collected from these patients every 3 months. cfDNA was extracted from 66 samples during the study period, and 10 ALK mutations were simultaneously evaluated. RESULTS: The numbers of samples showing the G1202R, C1156Y, G1269A, F1174L, T1151ins, and I1171T mutations were 32, 16, 5, 4, 1, and 1, respectively. The L1196M, L1152R, V1180L, and S1206Y mutations were not detected. Correlation analyses between progression-free survival and the time from treatment initiation (or treatment modification) to the detection of resistance mutations revealed that although resistance mutations may occur before a drug change becomes necessary, there is a duration during which the disease does not progress. CONCLUSIONS: Our findings suggest that real-time quantitative monitoring of ALK resistance mutations during the response period could provide a time course of changes while acquiring resistance mutations. This information would be beneficial for designing an appropriate treatment strategy.

    DOI： 10.21037/tlcr-22-671

    PubMed

    researchmap

  • 侵襲性肺炎球菌感染症を合併したCOVID-19の2例 Reviewed

    梅影泰寛, 奈良岡妙佳, 志垣涼太, 木田涼太郎, 森千惠, 佐々木高明

    日本呼吸器学会誌   12 ( 3 )   125 - 129   2023.5

    　More details

    Authorship：Lead author,　Corresponding author   Language：Japanese   Publishing type：Research paper (scientific journal)  

    researchmap

  • Case Report: Case series: association between blood concentration and side effects of sotorasib. International journal

    Ryota Shigaki, Ryohei Yoshida, Akari Yagita, Kazunori Nagasue, Taeka Naraoka, Kiichi Nitanai, Hiraku Yanada, Toshiyuki Tenma, Ryotaro Kida, Yasuhiro Umekage, Chie Mori, Yoshinori Minami, Hideki Sato, Kuninori Iwayama, Yasuhisa Hashino, Masahide Fukudo, Takaaki Sasaki

    Frontiers in oncology   13   1269991 - 1269991   2023

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    INTRODUCTION: Sotorasib is a crucial therapeutic agent for patients with non-small cell lung cancer (NSCLC) harboring the KRAS p.G12C mutation. Despite its efficacy, the relationship between blood sotorasib concentrations and side effects remains largely unexplored. METHODS: This study enrolled five patients with KRAS p.G12C-positive NSCLC treated with sotorasib (LUMAKRAS® Tablets, Amgen, Japan) between July 2022 and February 2023 at Asahikawa Medical University Hospital. Blood sotorasib levels were monitored, and their association with adverse events was examined, with no adjustments made to drug dosages based on these levels. RESULTS: Variable blood sotorasib levels were observed among the participants. Notably, one patient developed interstitial pneumonitis, although a definitive attribution to sotorasib was uncertain due to prior pembrolizumab treatment. The study revealed no consistent association between blood sotorasib levels and adverse events or therapeutic outcomes, with some patients experiencing severe side effects at higher concentrations, while others did not. CONCLUSION: Preliminary findings suggested that monitoring blood sotorasib levels may aid in anticipating adverse events in this small cohort. However, future studies with larger sample sizes and extended follow-up periods are required to validate these initial observations. Such studies could potentially offer insights into personalized dosing strategies, thereby mitigating adverse effects and enhance patient care for individuals with KRAS p.G12C-positive NSCLC.

    DOI： 10.3389/fonc.2023.1269991

    PubMed

    researchmap

  • 気管切開後に自然寛解した特発性気管狭窄の1例

    木田 涼太郎, 平井 理子, 鳴海 圭倫, 石田 健介, 森田 一豊, 梅影 泰寛, 風林 佳大, 山本 泰司, 佐々木 高明

    気管支学   44 ( 1 )   27 - 32   2022.1

    　More details

    Language：Japanese   Publisher：(一社)日本呼吸器内視鏡学会  

    背景.特発性気管狭窄は,原因不明の希少疾患で,治療法は確立されていない.内視鏡的治療や外科的治療は,再発率が高く声帯機能の温存が難しいことが指摘されている.症例.49歳女性.6ヵ月間呼吸困難を感じていた.初診時に吸気性喘鳴を聴取した.気管支鏡で声帯下2cmの部位に全周性の気管狭窄を認めた.気道確保のため,狭窄遠位側で気管切開を行った.気管切開後に行った狭窄部の生検で,炎症細胞浸潤を伴う非特異的な線維性組織を認めた.気管狭窄を来す他の疾患は否定的であり,特発性気管狭窄と診断した.2ヵ月後,再入院し気管支鏡を行ったところ,気管狭窄は自然軽快していたため,根治術は行わなかった.さらに2ヵ月後,気管狭窄は全周性に寛解していたため気管孔を閉鎖した.以後3年間再狭窄を認めていない.結論.本症例は,気管切開下での自然寛解を期待した経過観察が,特発性気管狭窄の治療選択肢の一つとなり得る可能性を示した.(著者抄録)

    researchmap

    Other Link： https://search.jamas.or.jp/default/link?pub_year=2022&ichushi_jid=J00298&link_issn=&doc_id=20220218260006&doc_link_id=%2Fcf0brond%2F2022%2F004401%2F007%2F0027-0032%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcf0brond%2F2022%2F004401%2F007%2F0027-0032%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • Cyclin-dependent kinase 4 upregulation mediates acquired resistance of dabrafenib plus trametinib in BRAF V600E-mutated lung cancer. International journal

    Noriko Hirai, Yutaka Hatanaka, Kanako C Hatanaka, Yuji Uno, Shin-Ichi Chiba, Yasuhiro Umekage, Yoshinori Minami, Shunsuke Okumura, Yoshinobu Ohsaki, Takaaki Sasaki

    Translational lung cancer research   10 ( 9 )   3737 - 3744   2021.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Combination therapy with the B-Raf inhibitor, dabrafenib, and the MEK inhibitor, trametinib (DT) is commonly used to treat patients with B-Raf proto-oncogene, serine/threonine kinase V600E (BRAF V600E)-mutated non-small cell lung cancer (NSCLC). However, the mechanisms through which cancer develops DT resistance are unclear. Here, we investigated new mechanisms underlying acquired DT-resistant NSCLC with the BRAF V600E mutation. METHODS: We compared genomic signatures before and after DT treatment in patients with NSCLC. RESULTS: Two of four patients treated with DT developed carcinomatous pleuritis within 3 months. Target DNA sequencing and quantitative polymerase chain reaction (PCR) analyses revealed the increased expression level of cyclin-dependent kinase 4 (CDK4). We also found prominent protein expression of CDK4 after DT treatment. Induction of CDK4 expression in a cell line derived from a patient with the BRAF V600E mutation resulted in partial resistance to dabrafenib. CONCLUSIONS: Our findings suggest a possible relationship between CDK4 upregulation and acquired resistance to DT therapy.

    DOI： 10.21037/tlcr-21-415

    PubMed

    researchmap

  • Acute eosinophilic pneumonia following inhalation of turpentine oil: A case report Reviewed

    Yasuhiro Umekage

    Respiratory Medicine Case Reports   2020.7

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.rmcr.2020.101143.

    researchmap

  • Highly sensitive detection of ALK resistance mutations in plasma using droplet digital PCR. International journal

    Ryohei Yoshida, Takaaki Sasaki, Yasuhiro Umekage, Sachie Tanno, Yusuke Ono, Munehiko Ogata, Shinichi Chiba, Yusuke Mizukami, Yoshinobu Ohsaki

    BMC cancer   18 ( 1 )   1136 - 1136   2018.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: On-target resistance mechanisms found in one-third of patients receiving anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are secondary ALK mutations in ALK-rearranged non-small cell lung cancer (NSCLC). There are large variations in the resistant mutations, unlike the epithelial growth factor receptor (EGFR) T790 M seen with the use of EGFR-TKIs. Liquid biopsy approaches using cell-free DNA (cfDNA) are used for screening and monitoring of mutations in NSCLC. However, feasible protocol for the simultaneous detection of multiple secondary ALK mutations using droplet digital PCR (ddPCR) has not been developed. An efficient strategy using cfDNA in cancer diagnostics, the development of more accurate and cost-effective tools to identify informative multiple secondary ALK mutations is clinically required. METHODS: To establish a feasible assay to monitor ALK-TKI resistance mutations, we first evaluated the feasibility of ddPCR-based screening for cfDNA mutation detection of 10 distinct secondary ALK mutations. Positive samples were then re-analyzed using mutation-specific probes to track the growth of mutation clones with a high sensitivity. RESULTS: Blood samples from seven ALK-positive patients were analyzed using the ddPCR protocol. Secondary G1202R ALK mutations were identified in 2 of 7 patients by the screening assay. Using the mutation-specific probes, monitoring the resistant clone during the clinical course of the disease was well demonstrated in each of the patients. CONCLUSION: The protocol for ddPCR-based liquid biopsy has a feasibility for the screening of secondary ALK-TKI resistance mutations and offers a tool for a cost-effective monitoring of progression in NSCLC.

    DOI： 10.1186/s12885-018-5031-0

    PubMed

    researchmap

▼display all

MISC

▼display all

Presentations

▼display all

Research Projects

  • 流行性ウイルス感染症の院内感染を予測するエージェントベースモデルの開発

    Grant number：25K13558  2025.4 - 2028.3

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    梅影 泰寛

    　 More details

    Grant amount：\2,080,000 （ Direct Cost: \1,600,000 、 Indirect Cost：\480,000 ）

    researchmap

Social Activities

  • 感染症の基礎知識と予防策

    Role(s)： Lecturer

    旭川医科大学公開講座  いのちを救う！「災害・救急・感染症(コロナ)」医療の最前線  2024.10

    　More details

  • 高齢者の呼吸器感染症

    Role(s)： Lecturer

    2022.7

    　More details

  • with コロナ時代のがん診療

    2022.1 - 2022.2

    　More details

    肺がんと薬物療法について動画配信

    researchmap